Why Private Equity Keeps Rolling Up Oral Surgery Practices

Why Oral Surgery Private Equity Has Become One of Healthcare's Most Active Deal Markets

Oral surgery private equity activity has accelerated sharply over the past decade, and the economics explain why. Oral surgery practices generate higher revenue per chair than almost any other dental specialty, carry lower insurance dependency than general dentistry, and remain highly fragmented at the ownership level. That combination is exactly what PE roll-up strategies require.

For high-net-worth investors evaluating healthcare fund allocations or co-investment opportunities, this sector deserves a closer look than it typically gets in standard portfolio conversations. The entry multiples are rich, the regulatory risk is real, and the exit thesis depends heavily on assumptions that fund marketing materials tend to gloss over.

The Investment Case: Why Oral Surgery Attracts Premium PE Valuations

Oral surgery practices typically trade at 8 to 14x EBITDA in private equity-backed acquisitions, according to PitchBook data tracking dental service organization transactions. That compares to 4 to 6x EBITDA for general dentistry practices. The premium reflects several structural advantages specific to the specialty.

Procedure revenue per visit is substantially higher. Implants, bone grafting, full-arch reconstructions, and orthognathic surgery generate case values that general dentistry cannot match. The patient mix also skews toward out-of-pocket and fee-for-service procedures, reducing the margin compression that comes with heavy Medicaid or HMO exposure.

Demand is durable. An aging population generates structural need for extractions, implants, and jaw reconstruction. That recurring, non-discretionary demand profile is exactly what PE underwriters want to see when modeling downside scenarios.

Platforms with $5M or more in EBITDA attract the most competitive bidding, per PitchBook benchmarks. Below that threshold, practices typically transact as add-ons to existing platforms rather than as standalone investments. For investors evaluating fund exposure, understanding where a fund's portfolio companies sit on that spectrum matters for assessing concentration risk.

The Bain and Company Global Healthcare Private Equity and M&A Report (2024) identifies dental and oral surgery as among the most active subsectors for platform acquisitions and add-on roll-ups, driven precisely by this fragmented market structure and the predictability of procedure demand.

Which Private Equity Firms Are Most Active in Oral Surgery Acquisitions?

Several firms have built meaningful oral surgery and dental service organization (DSO) positions. The landscape breaks into two tiers: large generalist PE firms with healthcare verticals, and dedicated healthcare-focused investors.

Gryphon Investors, Harvest Partners, and Thurston Group have been active in dental platform building. Heartland Dental, backed by KKR, represents one of the largest DSO platforms in the country, operating across multiple states with hundreds of affiliated practices. Aspen Dental, associated with Leonard Green and Partners, followed a similar consolidation trajectory over a longer timeline.

For oral surgery specifically, the AAOMS has noted increasing prevalence of PE-backed group practices within oral and maxillofacial surgery, driven by the specialty's high procedure revenue per visit. Smaller regional consolidators have also emerged, often backed by lower-middle-market PE firms targeting geographic density in specific metro areas before seeking a secondary buyout exit.

Leading healthcare-focused PE investors approach dental differently from hospital systems. The thesis is almost always roll-up driven: acquire a platform, bolt on add-ons at lower multiples, expand geographic density, and exit at a higher multiple to a larger strategic or another PE fund.

Knowing which firms are active matters if you are evaluating a healthcare PE fund's portfolio composition or considering a co-investment alongside a GP you already back.

What EBITDA Multiples Are Dental Service Organizations Paying for Oral Surgery Practices?

The multiple compression or expansion story in oral surgery PE is worth understanding precisely, because it drives the entire return thesis.

Platform acquisitions (the initial anchor practice) typically transact at the higher end of the range. Add-on acquisitions bolt onto the platform at lower multiples, often 5 to 8x, which is where the financial engineering creates value. The spread between add-on entry multiples and eventual exit multiples is the core return mechanism.

PitchBook's healthcare services data confirms that this multiple arbitrage strategy has been the primary driver of realized returns in dental roll-ups, not same-store organic growth. That distinction matters. If M&A markets seize up during a fund's hold period, the value creation thesis stalls. Investors who understand this going in can ask better questions about a fund's pipeline depth and add-on acquisition pace before committing capital.

How PE Deal Structures Work When Acquiring an Oral Surgery Practice

The typical transaction structure in oral surgery PE acquisitions involves a few consistent elements, though terms vary by deal size and platform maturity.

A PE firm acquires a majority stake, commonly 60 to 80 percent, in the operating entity. The founding surgeon or surgeon group retains a minority equity position and typically rolls that equity into the new structure rather than taking full cash at close. This rollover equity aligns incentives and keeps clinical leadership engaged through the hold period.

The legal architecture almost always involves a Management Services Organization structure. Because most states prohibit non-dentists from owning dental practices outright under corporate practice of dentistry (CPOD) laws, the PE firm owns the MSO, which provides management, administrative, and business services to the clinical practice. The dentist retains nominal ownership of the clinical entity.

For surgeons evaluating a PE offer, the rollover equity percentage and the exit multiple assumption embedded in the deal model are the two numbers that determine whether the transaction creates real wealth. A surgeon rolling 20 percent equity into a platform targeting a 12x exit on $10M EBITDA is looking at a very different outcome than one rolling into a platform with a compressed exit assumption and heavy leverage.

Understanding what happens when PE firms acquire practices in detail is essential before signing anything.

How Does Private Equity Ownership Affect Oral Surgery Patient Outcomes and Costs?

The evidence here is mixed, and anyone telling you otherwise is either selling a fund or selling a lawsuit.

On the cost side, research published in Health Affairs found that private equity acquisition of healthcare practices is consistently associated with increased patient charges and shifts in service mix toward higher-margin procedures. The NEJM published analysis in 2022 finding that PE ownership of medical practices is associated with measurable increases in per-patient spending. Neither study focused exclusively on oral surgery, but the structural incentives that drive those outcomes apply directly to the specialty.

The concern is not that PE-backed practices are negligent. It is that the incentive structure creates pressure toward higher-margin case selection, upselling ancillary procedures, and optimizing scheduling for revenue per hour rather than patient throughput. Whether those pressures translate into worse clinical outcomes depends heavily on the specific platform and its governance.

On the access side, the capital infusion argument has merit. Many independent oral surgery practices lack the resources to invest in cone beam CT imaging, surgical navigation systems, or same-day implant workflows. PE-backed platforms can deploy that capital across multiple locations simultaneously. The ADA's annual survey data tracks the growing share of dentists employed by corporate entities, and the trend toward corporate ownership has coincided with expanded geographic access in some underserved markets.

The honest framing: PE ownership improves operational efficiency and capital deployment. Its effect on clinical quality is practice-specific and not reliably positive or negative at the sector level.

The MSO Structure and Regulatory Risk: What Investors Rarely Hear

This is the risk factor that fund marketing materials consistently underweight.

Corporate practice of dentistry laws prohibit non-dentists from owning dental practices in a significant number of states, including California, Texas, and New York. The MSO structure is the legal workaround: the PE firm owns the management company, which contracts with a dentist-owned clinical entity for administrative services. The clinical entity retains nominal independence; the MSO controls everything that matters operationally.

State dental boards and attorneys general have begun scrutinizing these arrangements more carefully. If a regulator determines that an MSO structure constitutes de facto ownership of a dental practice by a non-dentist, the consequences range from license revocation to forced divestiture of the clinical entity. That is a stranded asset scenario for the PE fund.

The FTC's 2023 challenge to Welsh, Carson, Anderson and Stowe's U.S. Anesthesia Partners roll-up is the clearest signal of where federal enforcement is heading. The FTC's 2022 policy statement on healthcare market enforcement explicitly identified dental and oral surgery roll-ups as areas of concern, citing evidence that reduced competition raises prices and reduces quality. Oral surgery consolidators controlling high shares of metropolitan market capacity face genuine antitrust exposure.

For investors in PE funds with dental exposure, the practical question is geographic concentration. A platform with 40 percent of oral surgery capacity in a single metro area is a different regulatory risk profile than one distributed across 15 states. Ask your GP for the geographic distribution of portfolio company market share before the next capital call.

The evolving private equity investment landscape in healthcare is being shaped as much by regulators as by deal markets right now.

How Oral Surgery DSO Roll-Up Returns Compare to Other Healthcare PE Investments

The return profile of dental and oral surgery PE investments sits in a specific range within the broader healthcare services universe. Understanding where it fits helps with portfolio allocation decisions.

The typical PE hold period for dental DSO platforms runs 4 to 7 years, with secondary buyouts (PE-to-PE transactions) being the most common exit route. The Aspen Dental and Heartland Dental trajectories both illustrate how platform scale, measured in practice count and geographic density, drives exit valuation rather than same-store organic growth. A fund exiting a 200-location platform commands a different multiple than one exiting a 30-location regional operator.

That means the return thesis depends on the M&A market being receptive at exit. In a credit-constrained environment, secondary buyouts become harder to execute at the entry multiple, and strategic buyers face their own capital constraints. This is the concentration risk that investors in dental roll-up funds should stress-test explicitly.

For context on similar transformations in medical specialties, radiology has gone through its own consolidation cycle with comparable dynamics.

Should High-Net-Worth Investors Consider DSO Funds for Portfolio Diversification?

The case for dental and oral surgery PE exposure as a portfolio allocation is real, but it is not the uncorrelated defensive play it is sometimes marketed as.

The genuine diversification argument rests on procedure demand being largely non-cyclical. Wisdom tooth extractions and implants do not get deferred the way elective cosmetic procedures do. The fee-for-service revenue mix reduces exposure to government reimbursement policy changes that affect hospital systems and physician groups. And the fragmented market structure means the roll-up opportunity is not yet exhausted, unlike some healthcare subsectors where consolidation is already advanced.

The counter-argument is that the return driver is financial engineering, not operational alpha. Multiple expansion through roll-up requires a functioning M&A market at exit. The leverage used to finance acquisitions amplifies both upside and downside. And the regulatory risk around MSO structures is a genuine tail risk that is difficult to price.

For investors already allocating to broader healthcare private equity trends, adding dental or oral surgery exposure through a specialist fund makes more sense than through a generalist fund with a small dental position. Specialist GPs have deeper deal flow, better operator relationships, and more sophisticated understanding of CPOD compliance across state lines.

The minimum check size for direct fund access typically starts at $1M to $5M for institutional-quality healthcare PE funds. Co-investment opportunities alongside established GPs can offer lower fee structures and direct exposure to specific platform investments, which is worth exploring if you have an existing GP relationship in healthcare.

Key private equity market statistics on healthcare fund performance provide useful benchmarks when evaluating manager selection in this space.

What the Regulatory and Antitrust Environment Means for Existing Investments

The FTC's posture toward healthcare consolidation has shifted materially since 2021, and oral surgery is not exempt from that shift.

The 2023 FTC challenge to the U.S. Anesthesia Partners roll-up backed by Welsh, Carson, Anderson and Stowe is the most directly relevant precedent. The FTC alleged that the roll-up strategy was designed to monopolize anesthesia markets in Texas, raising prices for patients and payers. The structural argument, that a PE-backed consolidator acquiring market share in a concentrated regional market creates anticompetitive harm, applies directly to oral surgery platforms in metro areas with limited specialist supply.

The FTC's 2022 enforcement policy statement on healthcare markets explicitly flagged dental consolidation as an area of active concern. For investors in funds with oral surgery platform exposure, the practical implication is that add-on acquisitions in already-concentrated markets may face regulatory challenge, slowing the roll-up pace and compressing exit timelines.

State-level enforcement adds another layer. Several state attorneys general have opened investigations into DSO practices, and dental board scrutiny of MSO structures has increased in California, New York, and Texas specifically. These are the three largest dental markets in the country.

None of this makes oral surgery PE uninvestable. It does mean that due diligence on any fund with dental exposure should include a specific review of geographic market concentration, MSO structure legal opinions, and the GP's track record navigating regulatory inquiries. Funds that cannot answer those questions clearly are not managing the risk. They are hoping it does not materialize.

Understanding how PE ownership impacts company performance under regulatory pressure is relevant context for any healthcare allocation.

The Surgeon's Perspective: Evaluating a PE Offer at the Practice Level

If you are an oral surgeon receiving a PE acquisition offer, or advising one, the financial analysis starts with a few specific numbers that determine whether the deal creates or destroys long-term wealth.

The entry multiple on your EBITDA sets the headline valuation. At 10x EBITDA on a $3M practice, you are looking at a $30M enterprise value. If you retain 25 percent rollover equity, your cash at close is roughly $22.5M and your rollover position is worth $7.5M at entry. Whether that rollover creates additional wealth depends entirely on the exit multiple the platform achieves.

The leverage ratio matters. PE firms typically finance acquisitions with a combination of equity and debt, often at 4 to 6x EBITDA in leverage. Higher leverage amplifies equity returns in a favorable exit but creates covenant risk and cash flow pressure if EBITDA growth stalls. Ask for the debt structure and covenant package before signing.

Clinical autonomy provisions in the management agreement determine your day-to-day reality post-close. PE firms control administrative and operational decisions through the MSO. Treatment protocols, referral relationships, and staffing decisions can shift toward centralized corporate standards. Surgeons who negotiate explicit clinical autonomy provisions into the MSO agreement tend to report better post-acquisition experiences.

The non-compete scope and duration is the clause that gets the least attention and causes the most regret. A five-year, 50-mile non-compete in a major metro area is effectively a career constraint if the partnership deteriorates. Negotiate this carefully.

For context on the scale of major private equity transactions in healthcare, the dental sector's deal sizes are modest relative to hospital system transactions but large relative to the individual practice owner's prior experience with capital markets.

The Outlook for Oral Surgery Private Equity Through 2027

The structural drivers that made oral surgery attractive to PE remain intact. Fragmented ownership, durable procedure demand, and fee-for-service revenue mix are not going away. But the easy phase of the cycle, when platforms could be assembled at reasonable multiples and exited quickly into a receptive M&A market, is likely behind us.

Entry multiples at 10 to 14x EBITDA leave limited room for error. A fund paying 12x on a platform today needs to exit at 14x or higher to generate target returns after fees and leverage costs. That requires either multiple expansion (dependent on market conditions) or significant EBITDA growth (dependent on operational execution and add-on pace). Both assumptions deserve scrutiny.

The regulatory environment will continue tightening. The FTC's healthcare enforcement posture is unlikely to soften materially regardless of administration changes, given bipartisan political pressure around healthcare costs. MSO structure risk in key states is a slow-moving but real constraint on platform growth.

The most credible opportunity for the next cycle is in platforms that have already achieved meaningful scale, have defensible geographic positions outside the most concentrated metros, and have invested in clinical differentiation (robotic surgery, same-day implant workflows, integrated sleep apnea treatment) rather than pure volume growth. Those platforms will attract strategic acquirers, not just secondary PE buyers, which broadens the exit option set and reduces dependence on PE market conditions.

Medical technology investment opportunities adjacent to oral surgery, including surgical navigation and digital workflow systems, represent a related allocation thesis worth considering alongside DSO exposure.

PE investment in service-based industries more broadly has followed similar consolidation and regulatory cycles, offering pattern recognition for where dental PE is likely heading.

References

• American Dental Association -- "Dentist Income, Gross Billings, and Expenses: Survey of Dental Practice" (2023)
• Federal Trade Commission -- "FTC Policy Statement on Enforcement Related to Healthcare Markets" (2022)
• Journal of the American Dental Association (JADA) -- "Corporate Dentistry and the Changing Landscape of Dental Practice Ownership" (2022)
• PitchBook -- "Healthcare Services Private Equity Report: Dental and Oral Surgery Sector" (2023)
• Health Affairs -- "Private Equity Investment in Health Care: An Overview of Hospital and Health System Leveraged Buyouts" (2021)
• New England Journal of Medicine -- "Private Equity Investment as a Divining Rod for Market Failure: Policy Responses to Harmful Physician Practice Acquisitions" (2022)
• Bain and Company -- "Global Healthcare Private Equity and M&A Report" (2024)
• American Association of Oral and Maxillofacial Surgeons (AAOMS) -- "AAOMS Practice Management Resources and Industry Data" (2023)